4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。
公示信息显示，药品“HJ-002-03片”适应症：EGFR突变的晚期非小细胞肺癌。
和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本26581.1033万人民币，实缴资本22593.9733万人民币。
通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。
主要股东信息显示，和径医药科技（上海）有限公司由上海联和投资有限公司持股54.8252%、上海径栎企业管理合伙企业（有限合伙）持股14.9999%、上海药明康德新药开发有限公司持股12.3443%、ZL CHINA HOLDING TWO LIMITED持股7.4066%、上海张江火炬创业投资有限公司持股5.4864%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.